Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival up to 10 years in patients with critical limb ischemia

  • 149 Accesses

  • 1 Citations

Abstract

To prospectively evaluate the potential influence of resistance to activated protein C (APC-resistance) on the initial inflammatory response, amputation rate and survival during 10 years of follow-up in patients with critical limb ischemia (CLI). Two hundred and fifty-six consecutive CLI patients were analyzed for APC-ratio, the Factor V Leiden mutation and inflammatory mediators and then prospectively followed for 10 years. Inflammatory mediators, amputation rate, morbidity and mortality were compared between patients with and without APC resistance. Of the 256 CLI patients, 35 (14 %) were heterozygotes and 2 (1 %) homozygotes for the Factor V gene mutation, whereas 219 (86 %) patients were non-APC resistant. No significant differences were found between APC resistant and non-APC resistant patients regarding inflammatory mediators. Non-APC resistant patients more often had infrainguinal atherosclerosis (172 [79 %] vs 22 [59 %]; p = 0.017). Amputation rate at 1 year did not differ. Furthermore, there were no significant differences between groups regarding 1-, 3-, 5-, or 10-year survival. APC resistance in patients with CLI was not related to inflammatory activity, and had no impact on limb salvage or rate of amputation or long-term mortality. APC-resistant CLI-patients less frequently had infrainguinal arteriosclerosis, however.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Norgren L et al (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45(Suppl S):S5–S67

  2. 2.

    Dormandy J, Heeck L, Vig S (1999) The natural history of claudication: risk to life and limb. Semin Vasc Surg 12(2):123–137

  3. 3.

    Imparato AM et al (1975) Intermittent claudication: its natural course. Surgery 78(6):795–799

  4. 4.

    Conte MS et al (2005) Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg 42(3):456–464; discussion 464–465

  5. 5.

    Goodney PP et al (2010) Factors associated with death 1 year after lower extremity bypass in Northern New England. J Vasc Surg 51(1):71–78

  6. 6.

    Isma N et al (2008) Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia. Angiology 59(5):542–548

  7. 7.

    Bertina RM et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475):64–67

  8. 8.

    Dunn ST et al (1998) Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease. Thromb Res 91(2):91–99

  9. 9.

    Eitzman DT et al (2005) Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation 111(14):1822–1825

  10. 10.

    Sampram ES et al (2003) Nature, frequency, and predictors of secondary procedures after endovascular repair of abdominal aortic aneurysm. J Vasc Surg 37(5):930–937

  11. 11.

    Sampram ES, Lindblad B (2001) The impact of factor V mutation on the risk for occlusion in patients undergoing peripheral vascular reconstructions. Eur J Vasc Endovasc Surg 22(2):134–138

  12. 12.

    Sampram ES, Lindblad B, Dahlback B (1998) Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg 28(4):624–629

  13. 13.

    Svensson PJ et al (1997) The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 241(5):379–385

  14. 14.

    Barani J et al (2005) Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg 42(1):75–80

  15. 15.

    Abou-Zamzam AM Jr et al (2007) A prospective analysis of critical limb ischemia: factors leading to major primary amputation versus revascularization. Ann Vasc Surg 21(4):458–463

  16. 16.

    Barani J et al (2005) Suboptimal treatment of risk factor for atherosclerosis in critical limb ischemia. Int Angiol 24(1):59–63

  17. 17.

    Barani J et al (2006) Cardiac function, inflammatory mediators and mortality in critical limb ischemia. Angiology 57(4):437–444

  18. 18.

    Dormandy JA, Rutherford RB (2000) Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31(1 Pt 2):S1–S296

  19. 19.

    Hirsch AT et al (2006) ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113(11):e463–e654

  20. 20.

    Sampram ES, Saad Y, Ouriel K (2008) Arterial thrombosis in mice with factor V Leiden mutation. Vascular 16(1):31–34

  21. 21.

    Sartori M et al (2011) Thrombotic risk factors and cardiovascular events after endovascular intervention for peripheral arterial disease. Eur J Vasc Endovasc Surg 42(6):817–823

  22. 22.

    Hillarp A, Zoller B, Dahlback B (1996) Activated protein C resistance as a basis for venous thrombosis. Am J Med 101(5):534–540

  23. 23.

    Bradbury AW et al (2010) Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: a description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classification. J Vasc Surg 51(5 Suppl):32S–42S

  24. 24.

    Holm J et al (1996) Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 239(3):221–226

  25. 25.

    Lindqvist PG et al (2003) Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system. J Thromb Haemost 1(3):601–602

  26. 26.

    Bradbury AW et al (2010) Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. Health Technol Assess 14(14):1–210, iii–iv

  27. 27.

    Bradbury AW (2010) Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial in perspective. J Vasc Surg 51(5 Suppl):1S–4S

  28. 28.

    Lawall H et al (2009) Long-term outcomes after medical and interventional therapy of critical limb ischemia. Eur J Intern Med 20(6):616–621

  29. 29.

    Schanzer A et al (2008) Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg 47(4):774–781

Download references

Acknowledgments

This study was supported by grants from the Ernhold Lundström Foundation, Research Funds at Malmö University Hospital, the Albert Påhlsson Foundation, and the Hulda Ahlmroth Foundation. We thank Barbro Palmqvist for skilful technical assistance.

Author information

Correspondence to Ellis S. Sampram.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sampram, E.S., Gottsäter, A., Lindblad, B. et al. APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival up to 10 years in patients with critical limb ischemia. J Thromb Thrombolysis 36, 288–292 (2013). https://doi.org/10.1007/s11239-012-0845-0

Download citation

Keywords

  • Arterial thrombosis
  • Critical limb ischemia (CLI)
  • Factor V Leiden
  • Activated protein C (APC) resistance